July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn
CapitalBio Technology raises over $113M in pre-IPO round
CapitalBio Corp. subsidiary CapitalBio Technology Co Ltd. raised over RMB800 million ($113 million) in a pre-IPO financing round last week led by Guangdong Boyi Design Institute Co. Ltd. with participation by Sinopec Group, Health 100, New Alliance Capital, Red Horse Investment, Jiaxing Qi’ao Equity Investment Partnership, Xiamen Xinding Investment, Suzhou Youcai Huiying Investment and Huzhou Jiasi Enterprise Consulting Service. The company, which markets biochip-based diagnostics, is planning an IPO on Shanghai’s STAR board.
Aidea raises $119M in Shanghai STAR IPO
Jiangsu Aidea Pharmaceutical Co. (Shanghai:688488) priced its IPO on Shanghai’s STAR board Monday, raising RMB839.4 million ($119.3 million) through the sale of 60 million shares at RMB13.99 and valuing the company at RMB5.9 billion. Aidea markets generic drug formulations and has completed Phase III testing for lead innovative candidate ACC007, a non-nucleoside reverse transcriptase inhibitor for HIV infection...